StockData

Lifecore Biomedical vs Maravai LifeSciences

LFCR and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LFCR and MRVI compare

Maravai LifeSciences is the larger company, worth 7.8 times as much as Lifecore Biomedical ($1.9B against $242M).

Lifecore Biomedical grew revenue faster over the last twelve months (0.47% versus −5.0% for Maravai LifeSciences).

Lifecore Biomedical keeps more of each dollar of sales as profit, with a net margin of −30.0% compared with −37.1% at Maravai LifeSciences.

Maravai LifeSciences scores higher on the StockData Score (7 against 4 for Lifecore Biomedical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLFCRMRVI
Size and price
Market cap$242M$1.9B
Share price$6.39$7.28
Change, 1 year−19.7%100%
Change, 5 years−26.3%−82.5%
Beta (5Y)2.000.31
Employees382435
StockData Score
Total score47 (better)
Valuation score1 (better)0
Growth score02 (better)
Performance score22
Health score13 (better)
Dividend score00
Valuation
P/S1.9× (better)9.1×
P/B–9.2×
FCF yield−5.6%−1.9% (better)
Fair value–$2.69
Margin of safety–−170%
Growth
Revenue growth (TTM)0.47% (better)−5.0%
Revenue growth, 5Y average−4.2% (better)−8.1%
Net income growth (TTM)−422%–
EPS growth (TTM)−485%–
Profitability
Gross margin31.3%34.9% (better)
Operating margin−13.4% (better)−56.1%
Net margin−30.0% (better)−37.1%
FCF margin−10.6% (better)−17.2%
Return on equity–−32.9%
Return on invested capital–−32.4%
Financial health
Debt / equity–0.72
Interest coverage−0.8× (better)−4.9×
Current ratio3.874.05 (better)
Altman Z-score−0.174.50 (better)
Piotroski F-score5 (better)2
Dividends and buybacks
Buyback yield−9.9%–
Shareholder yield−9.9%0.00% (better)
Ownership
Held by institutions67.1%55.5%
Held by insiders46.1%3.6%
Insider net buying, 12 months–$115K
Superinvestors holding1–
Short interest, % of float8.4%5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.